Tempus Ai Inc (TEM) - News Archive

In a landmark achievement, Tempus AI, Inc. (NASDAQ: TEM) has secured a 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its novel RNA-based Tempus xR IVD device. This development holds significant i...

Tempus AI Set to Showcase Precision Medicine Innovations at Morgan Stanley s 23rd Annual Global Healthcare Conference Tempus AI, Inc. (NASDAQ: TEM), a pioneering technology company leading the charge in artificial intel...

Investor Alert: Tempus AI, Inc. Faces Class Action Lawsuit Amid Investor LossesIn a significant development for shareholders of Tempus AI, Inc. (NASDAQ: TEM), the Pomerantz Law Firm has announced the initiation of a cla...

Leveraging AI in Psychiatry: Tempus Notetaker Revolutionizes Clinical DocumentationIn a significant leap for mental health care, Tempus AI, Inc. has unveiled its latest innovation, Notetaker, an artificial intelligence-...

Tempus AI Enlists Top Physicians to Revolutionize Oncology Research with New Advisory Board Tempus AI, Inc. (NASDAQ: TEM), a Chicago-based leader in AI-driven precision medicine, has made a significant stride in advanci...

Precision Medicine Revolution: Tempus AI s Groundbreaking Exhibitions at the 2025 American College of Cardiology Annual Meeting In the rapidly evolving domain of precision medicine, Tempus AI, Inc. (NASDAQ: TEM) stands...

In an era where artificial intelligence (AI) and precision medicine are becoming integral to cancer treatment, a significant collaboration has emerged between Tempus AI, Inc. and Stemline Therapeutics, a subsidiary of t...

Tempus AI, Inc. (NASDAQ: TEM), a technology company at the forefront of integrating artificial intelligence in precision medicine, is leveraging recent developments to solidify its standing in both cardiac care and onco...

Tempus AI to Present Groundbreaking Research at the 2024 Society for Immunotherapy of Cancer Annual Meeting Tempus AI, Inc. (NASDAQ: TEM), at the forefront of integrating artificial intelligence in precision medicine, h...

In a strategic move to bolster oncology research and development, Tempus AI, Inc. has announced an expansion of its collaboration with Takeda Pharmaceutical Company. This partnership, initially established to utilize Te...

Chicago - Tempus AI, Inc. (NASDAQ: TEM), a technology company at the forefront of artificial intelligence and precision medicine, continues to set new benchmarks in the healthcare sector. In a significant stride forward...

The Innovations in Precision Medicine: Tempus AI s Groundbreaking Validation Study In a significant advancement for precision medicine, Tempus AI, Inc. (NASDAQ: TEM), a company at the forefront of integrating artificial...

Tempus Surpasses 500 Research Publications: A Major Milestone for Artificial Intelligence in Precision MedicineTempus AI, Inc., a renowned player in the field of artificial intelligence (AI) and precision medicine, rece...

Tempus AI: Advancing Precision Medicine with New AMA Code and FDA Clearances Tempus AI, Inc. (NASDAQ: TEM), a pioneering entity in artificial intelligence and precision medicine, has announced several critical milestone...

Advanced Diagnostic Breakthroughs and AI Collaborations: Tempus AI Secures ADLT Status and Enters Strategic Partnership with United TherapeuticsTempus AI, Inc. (NASDAQ: TEM), a vanguard in artificial intelligence and pr...

Tempus Cleared by FDA for AI-based Algorithm that Identifies Patients at Risk of AFibIn a groundbreaking achievement, Tempus AI, Inc. has received clearance from the U.S. Food and Drug Administration (FDA) for its Tempu...

Tempus and United Therapeutics Collaborate to Pioneer AI-based Detection of Pulmonary Hypertension RiskTempus AI, Inc., a renowned player in the artificial intelligence (AI) and precision medicine sector, has recently u...